ArticleGut2016
A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.
Article in Gut, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Pooled it
- Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis.Scientific reports · 2017Pooled it
- Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.JCI insight · 2020Trial
- Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia.Experimental hematology · 2019Trial
- An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma.Journal of hepatology · 2026Article
- A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells.JHEP reports : innovation in hepatology · 2026Article
- Nidogen 1-enriched extracellular vesicles promote liver metastasis by inducing EMT and activating stellate cells.iScience · 2025Article
- AI-Assisted Drug Re-Purposing for Human Liver Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Hepatocyte delivery of miR-34b/c reduces hepatic stellate cell activation and improves liver fibrosis.Molecular therapy. Nucleic acids · 2025Article
- Reduction of alternative polarization of macrophages by short-term activated hepatic stellate cell-derived small extracellular vesicles.Journal of experimental & clinical cancer research : CR · 2025Article
- Colorectal cancer cells-derived exosomal miR-188-3p promotes liver metastasis by creating a pre-metastatic niche via activation of hepatic stellate cells.Journal of translational medicine · 2025Article
- Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis.Nature communications · 2025Article
- Targeting the liver clock improves fibrosis by restoring TGF-β signaling.Journal of hepatology · 2025Article
- Live-cell imaging of human liver fibrosis using hepatic micro-organoids.JCI insight · 2024Article
- Retrospective study evaluating association of colorectal tumors and hepatitis C virus.World journal of virology · 2024Article
- Article
- Orphan receptor GPR176 in hepatic stellate cells exerts a profibrotic role in chronic liver disease.JHEP reports : innovation in hepatology · 2024Article
- Hepatocyte FBXW7-dependent activity of nutrient-sensing nuclear receptors controls systemic energy homeostasis and NASH progression in male mice.Nature communications · 2023Article
- Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches.Journal of experimental & clinical cancer research : CR · 2023Review
- Hepatic Myofibroblasts: A Heterogeneous and Redox-Modulated Cell Population in Liver Fibrogenesis.Antioxidants (Basel, Switzerland) · 2022Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 6 institutions in 7 countries.
Funding
Abstract
objectiveWe used an informatics approach to identify and validate genes whose expression is unique to hepatic stellate cells and assessed the prognostic capability of their expression in cirrhosis.
designWe defined a hepatic stellate cell gene signature by comparing stellate, immune and hepatic transcriptome profiles. We then created a prognostic index using a combination of hepatic stellate cell signature expression and clinical variables. This signature was derived in a retrospective-prospective cohort of hepatitis C-related early-stage cirrhosis (prognostic index derivation set) and validated in an independent retrospective cohort of patients with postresection hepatocellular carcinoma (HCC). We then examined the association between hepatic stellate cell signature expression and decompensation, HCC development, progression of Child-Pugh class and survival.
resultsThe 122-gene hepatic stellate cell signature consists of genes encoding extracellular matrix proteins and developmental factors and correlates with the extent of fibrosis in human, mouse and rat datasets. Importantly, association of clinical prognostic variables with overall survival was improved by adding the signature; we used these results to define a prognostic index in the derivation set. In the validation set, the same prognostic index was associated with overall survival. The prognostic index was associated with decompensation, HCC and progression of Child-Pugh class in the derivation set, and HCC recurrence in the validation set.
conclusionsThis work highlights the unique transcriptional niche of stellate cells, and identifies potential stellate cell targets for tracking, targeting and isolation. Hepatic stellate cell signature expression may identify patients with HCV cirrhosis or postresection HCC with poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.